Y mAbs Therapeutics is a biotechnology business based in the US. Y mAbs Therapeutics shares (YMAB) are listed on the NASDAQ and all prices are listed in US Dollars. Its last market close was $4.41 – an increase of 4.26% over the previous week. Y mAbs Therapeutics employs 104 staff and has a trailing 12-month revenue of around $87.7 million.
The Finder Score crunches 147 key metrics we collected directly from 18+ brokers and assessed each provider’s performance based on nine different categories, weighing each metric based on the expertise and insights of Finder’s investment experts. We then scored and ranked each provider to determine the best brokerage accounts.
We update our best picks as products change, disappear or emerge in the market. We also regularly review and revise our selections to ensure our best provider lists reflect the most competitive available.
Paid non-client promotion. Finder does not invest money with providers on this page. If a brand is a referral partner, we're paid when you click or tap through to, open an account with or provide your contact information to the provider. Partnerships are not a recommendation for you to invest with any one company. Learn more about how we make money.
Finder is not an advisor or brokerage service. Information on this page is for educational purposes only and not a recommendation to invest with any one company, trade specific stocks or fund specific investments. All editorial opinions are our own.
| Latest market close | $4.41 |
|---|---|
| 52-week range | $3.84 - $17.47 |
| 50-day moving average | $4.78 |
| 200-day moving average | $9.56 |
| Wall St. target price | $16.10 |
| PE ratio | N/A |
| Dividend yield | N/A |
| Earnings per share (TTM) | $-0.67 |
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.
Historical closes compared with the close of $4.41 from 2025-05-02
| 1 week (2025-04-25) | 7.56% |
|---|---|
| 1 month (2025-04-04) | -2.86% |
| 3 months (2025-02-05) | -28.99% |
| 6 months (2024-11-05) | -70.79% |
| 1 year (2024-05-03) | -74.29% |
|---|---|
| 2 years (2023-05-04) | -28.64% |
| 3 years (2022-05-04) | 10.14 |
| 5 years (2020-05-04) | 33.8 |
| Revenue TTM | $87.7 million |
|---|---|
| Gross profit TTM | $72.4 million |
| Return on assets TTM | -12.67% |
| Return on equity TTM | -30.74% |
| Profit margin | -33.83% |
| Book value | $2.05 |
| Market Capitalization | $199.7 million |
TTM: trailing 12 months
We're not expecting Y mAbs Therapeutics to pay a dividend over the next 12 months.
Over the last 12 months, Y mAbs Therapeutics's shares have ranged in value from as little as $3.84 up to $17.47. A popular way to gauge a stock's volatility is its "beta".
Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Y mAbs Therapeutics's is 0.702. This would suggest that Y mAbs Therapeutics's shares are less volatile than average (for this exchange).
Y-mAbs Therapeutics, Inc. , a commercial-stage biopharmaceutical company, focuses on the development and commercialization of radioimmunotherapy and antibody based therapeutic products for the treatment of cancer. It offers DANYELZA, a monoclonal antibody in combination with granulocyte-macrophage colony-stimulating factor for the treatment of pediatric patients with relapsed or refractory high-risk neuroblastoma in the bone or bone marrow. The company also develops DANYELZA for the treatment of patients with second-line relapsed osteosarcoma and is in Phase II clinical study; GD2-SADA, which is in Phase I clinical trial for the treatment of GD2 positive solid tumors; and Omburtamab, an antibody for the treatment of central nervous system/leptomeningeal metastases from neuroblastoma. In addition, it engages in the development of CD38-SADA and GD2-GD3 Vaccine; and offers self-assembly disassembly pretargeted radioimmuno therapy (SADA PRIT) technology platform to deliver the radioactive payload to the tumor. The company has a license agreement with Memorial Sloan Kettering Cancer Center and Massachusetts Institute of Technology to develop and commercialize licensed products. It operates in the United States, Western Europe, Eastern Asia, Latin America, Western Asia, and internationally.
Track the progress of the S&P 500 stocks to make more informed investment decisions.
See our picks for the best brokers for trading S&P 500 stocks, ETFs, options and futures.
These are the stocks to buy when you don’t have much to spend.
Explore the best bonuses for opening a new brokerage account.
Stock lending allows investors to loan out their existing stocks, although it has both advantages and disadvantages.
Compare pros, cons, research tools and reviews for these two trading platforms.
Some of the best trading apps like Robinhood are SoFi, Tastytrade, Public, eToro, Acorns, Interactive Brokers, E*TRADE and more.
Compare pros, cons, research tools and reviews for these two trading platforms.
SoFi Invest is a no-fee commissions platform with both active and automated investment accounts.
Webull is a broker with zero-commission trading and a suite of tools to help you invest.